GlobeNewswire

WSO2 Delivers Platform-Wide Support for GDPR with New Product Developments

Dela
WSO2 cloud-native, open source platform empowers enterprises to rapidly comply with EU data privacy requirements and create new GDPR-driven digital business offerings

MOUNTAIN VIEW, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- Time is running out to comply with the General Data Protection Regulation (GDPR) that goes into effect May 2018. Mandated by the European Parliament and European Union (EU) Council, the regulation is aimed at harmonizing data privacy laws across Europe to protect all data belonging to citizens and residents. As a result, it affects any enterprise that conducts business in or with EU markets. Significantly, in addressing GDPR's requirements, organizations have an opportunity to set the stage for new digital business models that drive revenues and growth. To support these enterprises, WSO2 today announced its Spring 2018 Release update, featuring product developments designed to offer platform-wide support for GDPR.

WSO2's Spring 2018 Release includes new features and updates across all products, solutions, and services, which together empower organizations to rapidly comply with GDPR. Among these are additions to WSO2's identity access management (IAM), API management, enterprise integration, and analytics offerings designed to ensure the security and privacy of personal data throughout the processes of collection, processing, storage, and destruction.

By delivering its functionality on a cloud-native, open source platform, WSO2 facilitates the agility and innovation required to thrive in rapidly evolving markets driven by disruptive technologies and digital business models. Now with WSO2's platform-wide support for GDPR, enterprises can accelerate their digital transformation efforts by capitalizing on data, insights and services generated through compliance with the regulation.

"In today's global economy, avoiding the GDPR data privacy mandate isn't an option. It will impact every organization worldwide that wants to engage with European residents online," said WSO2 CEO Tyler Jewell. "With our Spring 2018 Release, we are delivering the integrated products and services that will empower enterprises to comply with GDPR in as little as 60 days while laying the groundwork to deliver new digital products based on secure GDPR-compliant data."

In addition to the new product capabilities, WSO2 is offering a series of seven webinars to help organizations accelerate their GDPR compliance. To learn more about the GDPR implementation best practices covered in the webinars, as well as how to participate, visit https://wso2.com/solutions/regulatory-compliance/gdpr/#Events.

Facilitating GDPR Compliance
WSO2's Spring 2018 Release offers several technology developments designed not only to help organizations meet the regulatory requirements of GDPR, but also enhance their long-term growth potential through new services and greater efficiency.

Consent management and privacy toolkit in  WSO2 Identity Server enable enterprise data controllers to accelerate their organization's GDPR compliance. In addition to the new consent management functionality and the privacy toolkit, the Spring 2018 Release of WSO2 Identity Server also introduces personal information export capabilities and support for encrypting OpenID Connect identity tokens. Together, these new features address the different aspects of individual rights defined in GDPR, such as the "right to be forgotten" and the "right to personal data portability" among others, in order to ensure the protection of personal information.

Collaborative API and application lifecycle management with  WSO2 API Manager allows APIs and applications to be shared within and across organizations. The Spring 2018 product version also features the ability to anonymize user identities, in line with GDPR requirements to provide users with the right to be forgotten. If a user requests that personal data be removed from the system, organizations can anonymize that specific user's unique universal identification from multiple locations.

The API and application lifecycle management capabilities also can be deployed via a GDPR-compliant hybrid cloud solution that provides organizations a local gateway rather than a cloud API gateway. This lets users take advantage of the cloud's scalability and agility while ensuring that all API calls occur locally, thus increasing security and minimizing latency. Moreover, it is easy to maintain, since users simply supply their cloud credentials, and the gateway pulls the configuration and changes from the cloud.

Open source and GDPR-ready integration capabilities with  WSO2 Enterprise Integrator enable connections and data transformations across legacy systems, SaaS applications, services, and APIs. The Spring 2018 Release incorporates significant enhancements to scripting, caching, and analytics functionality that allow organizations to efficiently automate task execution and store data in a GDPR-compliant manner and gain insights into performance.

Streaming analytics capabilities with  WSO2 Stream Processor (formerly named WSO2 Data Analytics Server) empower organizations to derive meaningful insights with available data. The Spring 2018 version of the product includes functionality to support GDPR compliance, such as the ability to anonymize both login user information and any data stored in databases.

WSO2 Open Banking  for financial firms,  which launched in August 2017, complements today's new product releases by providing the functionality to comply with both GDPR and the European Union's second Payment Services Directive (PSD2). Security features that support full GDPR compliance include user consent, user profile management, and cookie handling, among others.

Enhanced Subscription Benefits
WSO2's Spring 2018 Release product developments are complemented by enhancements to WSO2 Subscription, WSO2's commercial offering, which features access to WSO2 Update for continuous delivery of bug fixes, security updates, and performance enhancements, along with WSO2 Support for 24x7 support. Among the enhanced WSO2 Subscription benefits are the increase of support lifetime for WSO2 product versions to 10 years; new installation options, including Docker images, Docker Compose, and Vagrant; and a new release of WSO2 Update Manager. In addition to the included solutions and services, WSO2 Subscription offers options for training, consulting, and WSO2 Managed Cloud services.

Enterprises also can take advantage of a free 15-day trial of WSO2 Subscription to assist users evaluating WSO2 products and services. A Free Trial Subscription provides access to an account management and solution architecture team, along with access to all Subscription benefits, including five hours of query support.

About WSO2
WSO2 is the #1 open source integration vendor. It offers a complete platform that enables businesses to integrate, manage, govern and process any application, data or system-on-premises or in the cloud. Enterprises and governments across the world rely on WSO2's consulting and subscriptions that accelerate the evolution of any digital native initiative. Today, over 450 enterprise customers representing the world's best brands, process more than 5 trillion transactions through WSO2 each year. Visit https://wso2.com to learn more.

Trademarks and registered trademarks are the properties of their respective owners.

PR Contact
Shifali Erasmus
Kinetic.PR, LLC for WSO2
shifali@kineticprllc.com
Mobile: 650-544-6424




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: WSO2, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum